Florian Lordick/LinkedIn
Jul 7, 2025, 12:20
Florian Lordick: Triplet Therapy Shows Promising Activity in Gastroesophageal Cancer
Florian Lordick, Professor of Medicine at the University of Leipzig, shared a post on LinkedIn:
“Preliminary data from a phase Ib Clinical Trial presented at ESMOGI25 suggest that a triple combination of givastomig (a first-in-class claudin [CLDN]18.2/4-1BB bispecific antibody), nivolumab and mFOLFOX has promising activity and an acceptable safety profile in patients with HER2-negative, CLDN18.2-positive, metastatic GastroEsophageal adenocarcinoma.
Responses occurred irrespective of PDL1 combined positive score and in patients with <75% CLDN18.2.
There were no dose-limiting toxicities and the maximum tolerated dose was not reached.
Read the full article in the ESMO Daily Reporter.”
More posts featuring Florian Lordick.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 7, 2025, 11:44
Jul 7, 2025, 11:34
Jul 7, 2025, 11:25
Jul 7, 2025, 11:17
Jul 7, 2025, 11:03
Jul 7, 2025, 10:48